Results for
""Dabigatran""[mesh_terms]

Dabigatran must be used carefully: literature review and recommendations for management of adverse events.

Wei Guan, Lei Zhang, Yan Wang, Shan Lin

Drug design, development and therapy 2020;13():1527-1533

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

Gillian M Keating, Hannah A Blair

Drugs 2017;77(3):331-344

Determination of dabigatran in human plasma samples.

Job Harenberg, Christina Giese, Svetlana Marx, Roland Krämer

Seminars in thrombosis and hemostasis 2012;38(1):16-22

Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study.

Walter Ageno, Samuel Z Goldhaber, Ivan B Casella, Sam Schulman, Wenbo Tang, Isabelle Voccia, Daniel E Singer, Sebastian Schellong, Kok Han Chee

Journal of thrombosis and thrombolysis 2022;53(2):399-409

Warfarin versus dabigatran: comparing the old with the new.

Todd R Marcy, Mary Elizabeth Abraham

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2012;27(2):121-4

Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.

Julia Paik

Paediatric drugs 2022;24(4):423-431

The oral thrombin inhibitor dabigatran: strengths and weaknesses.

Ammar Majeed, Sam Schulman

Seminars in thrombosis and hemostasis 2012;38(1):7-15

Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update.

Ke Xu, Noel C Chan, John W Eikelboom

Expert opinion on drug metabolism & toxicology 2021;17(9):1091-1102

Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies.

Yi-Min Cui, Qian Xiang, Kun Hu, Zhe Wang, Zhi-Yan Liu, Zi-Ning Wang, Shuang Zhou, Qiu-Fen Xie, Guang-Yan Mu, Ling-Yue Ma, Han-Xu Zhang

BMC cardiovascular disorders 2022;22(1):105

Present Knowledge on Direct Oral Anticoagulant and Novel Oral Anti Coagulants and Their Specific Antidotes: A Comprehensive Review Article.

Adrija Hajra, Wilbert S Aronow, Rahul Gupta, Sheetal Vasundhara Mathai, Israel Safiriyu, Abdul Rasheed Bahar, Yasemin Bahar, Suman Biswas

Current problems in cardiology 2023;48(2):101483

An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs).

Selman Yeniocak, Mandana Hosseinzadeh, Bilgen Ozkaya, Sehmus Zengin, Derya Abuşka, Eylem Ersan, Göksu Afacan, Sarper Yilmaz, Ozgur Karcioglu

Cardiovascular & hematological agents in medicinal chemistry 2022;20(2):114-124

Frontiers of anticoagulation therapy for atrial fibrillation.

Takeshi Yamashita

Journal of cardiology 2011;58(1):1-5

Pharmacokinetics and pharmacodynamics of direct oral anticoagulants.

B Hindley, P E Penson, A P McCloskey, G Y H Lip

Expert opinion on drug metabolism & toxicology 2024;19(12):911-923

Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial.

Maria C Escalante-Rojas, Daniel K Amado, Raphael R Spera, Iuri R Magalhães, Francisco A M Cardozo, Pai Ching Yu, Bruno Caramelli, Danielle M Gualandro, Paulo Caramelli, Ricardo Nitrini, Ana Carolina O Rodrigues, Sonia M D Brucki, Mariana G Matheus, Adriana F Pastana, Flavio A Borges-Junior, Caio A M Tavares, Daniela Calderaro

BMC medicine 2022;20(1):374

idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.

Prescrire international 2019;25(176):260-263